


ML-210

Cat. No.:	HY-100003		
CAS No.:	1360705-96-9		
Molecular Formula:	C ₂₂ H ₂₀ Cl ₂ N ₄ O ₄		
Molecular Weight:	475.32		
Target:	Glutathione Peroxidase; Ferroptosis		
Pathway:	Apoptosis; Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (52.60 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.1038 mL	10.5192 mL	21.0385 mL
		5 mM	0.4208 mL	2.1038 mL	4.2077 mL
10 mM		0.2104 mL	1.0519 mL	2.1038 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (5.26 mM); Suspended solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.38 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	ML-210 is a selective and covalent glutathione peroxidase 4 (GPX4) inhibitor with an EC ₅₀ of 30 nM. ML-210 binds the GPX4 selenocysteine residue. ML-210 has anti-cancer activity ^{[1][2]} .
IC₅₀ & Target	Glutathione Peroxidase 4 (GPX4) ^[1]
In Vitro	<p>ML-210 exhibits cell-killing activity across a panel of 821 cancer cell lines (WM88, LOX-IMVI, CJM, U257, CAK12, A498, HT1080, MC38, PANC02). ML-210 is a prodrug that requires cellular activation to bind GPX4^[1].</p> <p>ML-210 has IC₅₀s of 71 nM, 272 nM and 107nM for BJeLR (HRAS_{V12}), BJeH-LT (without HRAS_{V12}) and DRD cell lines, respectively^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

CUSTOMER VALIDATION

- Cell Discov. 2022 May 3;8(1):40.
- Nat Chem Biol. 2024 Jan 11.
- Small. 2021 Oct 8;e2103919.
- Cell Mol Life Sci. 2024 Jan 22;81(1):49.
- Am J Cancer Res. 2023 Feb 28.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. John K. Eaton, et al. Targeting a Therapy-Resistant Cancer Cell State Using Masked Electrophiles as GPX4 Inhibitors. Biorxiv. 2018.
- [2]. Weïwer M, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1822-6.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA